Abstract
De novo acute myeloid leukemia (AML) is a heterogeneous clinical disorder characterized by a variety of cytogenetic abnormalities and gene mutations (e.g., FLT3 or NPM1 ) that correlate with complete remission following induction chemotherapy, as well as with overall survival (JW Oncol Hematol May 13 2008). Mutations in the RAS oncogene (mut RAS ) also have been reported in AML, with these cells showing enhanced cytarabine sensitivity in vitro (Cancer Res 1999; 59:6057). Investigators performed a retrospective analysis of 185 adult de novo AML patients who participated in the Cancer and Leukemia Group B (CALGB) …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
